All companies
Axogen logo

What smart money is saying about AxogenUnited States flag

AXGN · Healthcare · Medical - Devices · Market cap $1.42B

1 fund in our archive has pitched Axogen, most recently Brown Capital Small Company Fund in September 2025.

Company profile

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Get an email when a fund buys, sells or pitches it

Summarize with Warren AI
1
Reported positions
1
Bought
0
Sold
1
Letter

Position history

Every position in Axogen on record in the archive was reported in Q3 2025, across 1 fund letter, with 1 buy (opened or added).

Fund letters reporting a position in Axogen, by quarter
QuarterLettersBoughtSoldTheses
Q3 20251101

Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.

Fund activity · 1 position · 1 move

Fund coverage · 1 thesis

Read every full thesis on Axogen

Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.

View plans→
Share this ledger